Modulation of the T-cell compartment by blood transfusion : effect on cytotoxic and helper T lymphocyte precursor frequencies and T cell receptor V-beta usage by Mast, B.J. van der et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/24422
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
0041-1337/97/6308-1145$03.00/0
T r a n spl a n t a t io n
Copyright © 1997 by Williams & Wilkins
Vol. 63, 1145-1154, No. 8, April 27, 1997
Printed in U.S.A,
MODULATION OF THE T CELL COMPARTMENT BY BLOOD 
TRANSFUSION
Effect on Cytotoxic and Helper T Lymphocyte Precursor Frequencies and T Cell Receptor V/3 Usage1
Barbara J. van der Mast,2,3,4 Henk E. Viëtor,4,5 Ellen M.W. van der Meer-Prins,2 
Simone P.M.J. van Bree,2 Anneke Brand,2 Peter J. van den Elsen,2 and Frans H.J. Claas2
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R ecent data suggest that the favorable effect of pre­
tran sp lan t blood transfusion (BT) on transplant out­
c o m e  depends on the HLA match. HLA-DR or haplo- 
t y p e  shared transfusions lead to transplantation  
to lera n ce , and HLA-mismatched BT leads to immuni­
z a t io n . The im m unological mechanism involved is still 
u n k n ow n . To investigate the effect of HLA compatibil­
i t y  betw een  blood donor and recipient on the T cell 
com partm ent, w e determ ined the frequency of cyto­
t o x ic  and helper T cell precursors specific for blood 
d o n o r  cells (n=20) and the T cell receptor Vß (TCRBV) 
rep er to ire  of th e CD4- and CD8-positive peripheral 
b lo o d  m ononuclear cells before, at 2 weeks after, and 
a t  m ore than 10 w eeks after BT (n=10). Patients had  
r e c e iv e d  one transfusion of a nonstored (<24 hr after 
w ith d raw al) erythrocyte concentrate without buffy 
c o a t  containing on average 6 x10s leukocytes. Eight 
p a tie n ts  shared an HLA-B and -DR antigen, nine pa­
t ie n t s  shared one HLA-DR antigen, and three patients 
sh a r e d  no HLA class II antigens with the blood donor. 
A ll  patients show ed a significant increase in  both cy­
to to x ic  and helper T cell precursor frequencies 
a g a in s t  the blood donor 2 weeks after BT. In most 
p a tie n ts , the frequencies reached pretransfusion lev­
e l s  again long after BT. In 5 of 10 patients, an expan­
s i o n  of one or m ore TCRBV families was observed in  
e i t h e r  the CD4 or CD8 compartment.
T h is  study dem onstrates that BT, irrespective of the 
d e g r e e  of HLA m atching, induces activation of the T 
c e l l  compartm ent. The degree of sharing of HLA anti­
g e n s  was not correlated w ith quantitative changes in  
c y to to x ic  T lym phocyte precursor or helper T lympho­
c y t e  precursor frequencies, or changes induced in the 
T C R B V  repertoire. Cytotoxic and helper T lymphocyte 
p recu rso r  frequencies and TCRBV repertoire deter­
m in e d  after BT do not give an indication for a state of 
to le r a n c e  prior to  transplantation.
Induction of donor-specific tolerance is the major goal in 
o rg a n  transplantation. In humans, there is evidence that the
1 This study was supported by the Macropa Foundation and the 
J.A. Cohen Institute for Radio Pathology and Radiation Protection
( 1 R S ) .
2 Department of Immunohematology and Blood Bank.
3 Address correspondence to: Barbara J. van der Mast, Depart­
m e n t  of Immunohematology and Blood Bank, Building 1, E3-Q, 
U niversity  Hospital Leiden, P.O. Box 9600, 2300 RC Leiden, The
N etherlands.
4 Both authors contributed equally to the realization of the manu­
sc rip t.
5 Department of Obstetrics.
administration of blood has a favorable effect on graft sur­
vival (1). Although the immunological mechanisms involved 
are still unknown, it is clear that many factors may influence 
this (beneficial) effect. The presence of viable leukocytes in 
the transfused blood seems essential, as infusion of filtered, 
leukocyte-depleted blood was ineffective in enhancing kidney 
graft survival (2). However, the number of leukocytes needed, 
their specific characteristics, time of storage of the trans fu­
sate, the recipient’s immune status, HLA matching, the op­
timal number of transfusions, and the timing of the transfu­
sions in relation to transplantation have yet to be assessed.
Several studies have indicated that the beneficial effect of 
a pretransplant blood transfusion (BT*) has diminished dur­
ing the last decade. Improved patient care, introduction of 
cyclosporine, and better rejection diagnosis and treatments 
have resulted in better graft survival in patients who do not 
receive transfusions (3-5). However, other studies still show 
a transfusion effect even in the cyclosp orine era (6} G. Opelz, 
Institute of Immunology, University of Heidelberg, Germany, 
personal communication, 1996). Therefore, the issue of 
whether pretransplant BTs still have a beneficial effect on 
graft survival remains controversial.
Studies in animal models and in man have led to several 
hypotheses concerning the mechanism of the BT effect, in­
cluding clonal deletion of donor-reactive cells (7), induction of 
suppressor cells (£), veto cells (9) and CD4+ regulatory cells
(10), and the formation of anti-idiotypic antibodies (11). The 
induction of permanent mixed chimerism has been suggested 
to be essential for induction of transplantation tolerance (12, 
13). In the majority of mechanisms proposed, T cells play an 
important role.
Recent studies have shown that the degree of HLA match­
ing between transfusion donor and recipient plays a pivotal 
role in the immunomodulating effect of BTs. BT with a 
shared HLA-DR antigen results in better graft survival and 
a decreased number of rejection episodes in kidney and heart 
allograft recipients compared with HLA-DR-mismatched BT 
(14-16a). Furthermore, a one-HLA-DR-antigen-shared BT 
has a decreased risk of inducing alio antibodies compared 
with a two-HLA-DR-antigen-mismatched BT (14). In vitro 
studies have shown that nonresponsiveness of cytotoxic T 
lymphocytes (CTLs) against the blood donor occurs in pa-
* Abbreviations: BT, blood transfusion; CTL, cytotoxic T lympho­
cyte; CTLp, cytotoxic T lymphocyte precursor; HTLp, helper T lym­
phocyte precursor; IL, interleukin; LDA, limiting dilution analysis; 
PBMC, peripheral blood mononuclear cells; PCR, polymerase chain 
reaction; TCRBV, T cell receptor Vß.
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tients waiting for a kidney transplantation who had received 
a haplotype (or at least one HLA-B and one HLA-DR anti- 
gen)-shared BT (17). In these patients, CTLs directed against 
the blood donor had a low avidity for their target (as deter­
mined by CD8 blocking). In contrast, a high avidity was 
found for do nor-specific CTLs generated by a non-HLA- 
shared BT (18). The same group also demonstrated deletions 
in the T cell receptor Vß (TCRBV) repertoire in patients who 
received a haplotype-shared BT (19).
In the present study, we investigated in more detail the 
effect of HLA compatibility between blood donor and recipi­
ent on the T cell allorepertoire of potential renal transplant 
recipients. We focused on the determination of the frequen­
cies of cytotoxic T lymphocyte precursors (CTLp) and helper 
T lymphocyte precursors (HTLp) specific for donor cells be­
fore, at 2 weeks after, and at more than 10 weeks after BT. Of
10 patients, the TCRBV gene usage of circulating T cells was 
determined both before and after BT. Since the TCRBV rep­
ertoire of single positive CD4+ and CD8+ cells displays dif­
ferent usage patterns (20 > 21), the effect of BT on the TCRBV 
gene usage of these two subsets was analyzed separately.
MATERIALS AND METHODS
Patients. Twenty-one patients waiting for a kidney transplanta­
tion received transfusions between 1989 and 1995 according to a 
study protocol to improve graft survival. None of these patients had 
a BT history. Women with previous pregnancies were excluded from 
this study. All patients received 1 U of nonstored (<24 hr after 
withdrawal) erythrocyte concentrate, the buffy coat of which was 
removed. The transfusate contained an average of 6X108 leukocytes. 
Heparinized blood samples from the patient were taken before, 2 
weeks after, and at a time varying between 10 weeks and 58 months 
after transfusion. All samples were taken before transplantation. 
Blood donor peripheral blood mononuclear cells (PBMC) were iso­
lated from the buffy coat. At the time of transfusion, the patients did 
not receive immunosuppressive therapy. Patients, blood donors, and 
healthy (third-party) volunteers were HLA-typed for class I and class
11 antigens by conventional serological methods, based on comple­
ment-dependent cytotoxicity. HLA typing of patients and blood do­
nors and timing of the third blood sample are shown in Table 1.
Isolation and storage of lymphocytes. PBMC were isolated using a 
Ficoll-amidotrizoaat density gradient centrifugation procedure. He­
parinized blood was diluted 1:1 with Hanks* balanced salt solution 
(Gibco, Paisley, UK), layered on the gradient, and centrifuged for 15 
min at 600 X.g. PBMC isolated from the interface were washed twice 
with Hanks5 balanced salt solution and frozen in RPMI 1640 medium 
(Gibco) with 20% fetal calf serum (Bodinco, Alkmaar, Holland) and 
10% dimethyl sulfoxide (Fluka, Buchs, Switzerland). The cells were 
frozen at -70°C and then stored in liquid nitrogen until needed.
Limiting dilution assay. The analysis of CTLp frequencies di­
rected against the blood donor was based on the principle of limiting 
dilution analysis (LDA) (22). Responder lymphocytes (patient 
PBMC), re suspended in RPMI 1640 medium with 3 mM L-glutamine 
supplemented with 10% pooled human serum (referred to as com­
plete medium), were set up in 12 replicate wells at 40,000 cells/well 
and were diluted twofold (from 40,000 cells/well down to 625) across 
the wells of two 96-well U-bottom plates (Costar, Cambridge, MA). 
Responder cells were excluded from the last 12 wells. Individual sera 
included in the serum pool and used in the culture medium were 
tested in a mixed lymphocyte culture assay using three different 
responder-stimulator combinations. They were excluded from the 
pool if inhibitory or stimulatory effects on proliferation were present. 
Stimulator lymphocytes (blood donor PBMC or third-party PBMC 
mismatched for HLA class I and II antigens with patient and blood 
donor) were irradiated with 3,000 rads (137Cs source; Isomedix, Par-
sippany, NJ) and added in complete medium to the responder cells at 
a concentration of 50,000 cells/well. Responder and stimulator cells 
were cultured in the presence of 20 U/ml human interleukin (IL) 2 
(Cetus, Amsterdam, The Netherlands) for 7 days. After 5 days of 
culture, half the medium was changed for fresh complete medium 
containing rIL-2 at 20 U/ml. Lymphocytes to be used as target cells 
were set up at the beginning of the culture period in complete 
medium containing 20 U/ml rIL-2 and 2 ¡¿g/ml purified phytohem­
agglutinin (Welcome, Dartford, UK) at a cell density of 1X106 cells/ 
ml/well in a 24-well plate (Costar). Target cells were refreshed on 
days 3 and 5 with complete medium containing 20 U/ml of rIL-2. 
After 7 days of culturing, target cells were labeled with europium - 
DTPA, as described previously (23). Targets of the stimulator type 
were added at a concentration of 5,000 cells/well to each responder- 
stimulator combination that had been split into two identical por­
tions, one of which was incubated for 1 hr at room temperature with 
an anti-CD8 monoclonal antibody (24) to study the effect of CD8 
molecule blockade on CTLp frequencies (25, 26). The plates were 
then incubated for 4 h ra t3 7 °C in 5 % C 0 2. After centrifugation for 5 
min at 600 Xg, 20 pi of supernatant of each well were harvested and 
transferred to 96-well flat-bottom plates with a low background 
fluorescence (Fluoroimmunoplate, Nunc, Denmark). Additionally, 
200 pi of enhancement solution (Wallac, Turku, Finland) were added 
to each well. Fluorescence of the released europium was measured in 
a time-resolved fluorometer (Arcus 1234, Wallac). As a control for 
every target cell, spontaneous lysis (target cells + complete medium) 
and maximal lysis (target cells + 1% Triton X-100; Fluka) was 
determined. The CTLp frequencies of the different bleeding dates 
from each individual patient were determined in the same experi­
ment.
HTLp j CTLp combination test. In four patients, both HTLp and 
CTLp frequencies were determined in a single assay (27), Responder 
cells were set up in 24 wells at 20,000 cells/well and diluted twofold 
across the wells of two 96-well V-bottom plates (Greiner, Alphen aan 
de Rijn, The Netherlands). Twenty-five thousand stimulator cells, 
irradiated with 5,000 rads, were added per well. After 3 days of 
culture at 37°C in 6% C02, supernatant was harvested and trans­
ferred to U-bottom 96-well plates (Costar). The supernatants were 
stored at — 20°C until needed. The remaining cells were transferred 
to U-bottom plates (Costar) and were cultured for another 7 days at 
37°C in 5% C02 in the presence of 20 U/ml rIL-2. At day 7, half the 
medium was replaced with fresh complete medium containing rIL-2 
at 20 U/ml. Cell-mediated lympholysis was performed as described 
above. To determine the amount of IL-2 present in the supernatant, 
we used the lL-2-dependent murine CTLL-2 cell line. This CTLL-2 
cell line was kept in culture continuously in RPMI 1640 medium 
supplemented with 3 mM L-glutam ine and 10% fetal calf serum 
(Bodinco) and 10 U/ml rIL-2. The assay was performed as described 
by Schanz et al. (28). In brief, the supernatants were thawed and 
CTLL-2 cells that had been put in IL-2-free medium for 20 to 24 hr 
were added at 3,000 cells/well to the plates. After incubation for 3 
days at 37°C in C02, lysing-staining-quenching medium containing 
Triton X-100 (Fluka), ink (Leitz, Wetzlar, Germany), and propidium 
iodide (Sigma, St. Louis, MO) in EDTA buffer was added. The plates 
were then read with an automated fluorescence microscope (Leica- 
Patimed, Wetzlar, Germany), which measures photometer values 
(mV) to determine the number of propidium-iodine-stained nucle­
ated cells and thus proliferation of the CTLL-2 cells. Since prolifer­
ation of the CTLL-2 cells is dependent on the amount of IL-2 present 
in the supernatants, this LDA can be used as a measure of the 
number of IL-2-secreting cells present in the responder cell fraction. 
As mainly T helper cells are considered responsible for IL-2 produc­
tion (29, 30), the HTLp frequency can be estimated.
Analysis of TCRBV usage. In 10 patients, the TCRBV gene usage 
was determined before and after BT.
After thawing, PBMC were stained with anti-CD4 (fluorescein 
isothiocyanate-conjugated) and anti-CD8 (phycoerythrin-conju- 
gated) monoclonal antibodies (Becton Dickinson, Mountain View,
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Table 1. HLA typing of patients and blood donors®
Patient HLA-A HLA-B HLA-DR Group TCRBV Sample >*10 w k^
1 Ma 33(19) 14, 50(21) 1, 12(5) 1 6 m o
Donor 1,2 8, 60(40) 7, 17(3)
2 Dur 1 8 4, 17(3) 1 10 w k
Donor 2, 11 44(12), 35 16(2), 7
3 Kam 24(9), 32(19)c 27, 35 1 1 16 m o
Donor 3, 30(19) 18, 35 4, 11(5)
4 Ba 3, 32(19) 14, 44(12) 12(5), 13(6) 2 2 4  m o
Donor 11, 30(19) 51(5), 55(22) 14(6)
5 Bu 2, 11 62(15), 38(16) 4,7 2 + 4  m o
Donor 3, 31(19) 57(17), 60(40) 11(5), 7
6 SI 3, 30(19) 18, 35 i  1K5) 2 + 3 m o
Donor 2, 23(9) 49(21), 27 1  14(6)
7 Ar 2 18, 51(5) 7, 13(6) 2 3 m o
Donor 1 8, 49(21) 13(6), 17(3)
8 Ka 2, 34(10) 45(12), 51(5) 15(2). 16(2) 2 + 4 6  m o
Donor 1,3 7 15(2). 8
9 Ve 2 44(12), 56(22) 1, 13(6) 2 + 4 1  m o
Donor 3, 31(19) 60(40) 1, 11(5)
10 Jo 1, 2 8, 39(16) 1, 17(3) 2 12 m o
Donor 2, 32(19) 57(17), 60(40) L 7
11 Vv 1, 32(19) 8, 44(12) 7, 17(3) 2 18 m o
Donor 2 61(40), 62(15) 4, 7
12 K1 3, 11 51(5), 62(15) 4, 13(6) 2 58  m o
Donor 1, 28 8, 35 3,4
13 Ra 1, 68(28) 8, 27 13(6). 17(3) 3 + 13 m o
Donor 1 7, 8 15(2), 17(3)
14 Ko 2, 3 7, 8 17(3), 15(2) 3 + 58  m o
Donor 1, 24(9) 7, 37 15(2). 10
15 Kp 2, 28 8, 14 17(3). 7 3 6 m o
Donor 1,2 8, 35 1, 17(3)
16 Wa 3, 31(19) 7 15(2) 3 14 m o
Donor 2, 31(19) 7, 39(16) 13(6). 15(2)
17 Be 2, 3 21(49), 35 1,4 3 6 m o
Donor 28, 31(19) 35 1, 15(2)
18 Du 1, 24(9) 8, 35 11(5), 17(3) 3 + 16 m o
Donor L  2 8, 62(15) 7, 17(3)
19 Ad 2, 3 44(12), 35 4, 14(6) 3 10 w k
Donor 1, 2 44(12) 11(5), 13(6)
20 Op 2, 24(9) 37, 51(5) 4,10 3 39  m o
Donor 1, 2 37, 60(40) 8, 10
21 Vo 3, 28 35, 53 L i m 3 + 35 m o
Donor 3, 28 35, 44 1. 13(6)
° HLA typing was based on serological typing methods.
* > 10 wk = timepoint long after BT.
c HLA-shared antigens between patient and blood donor are underlined.
CA) and separated using a fluorescence-activated cell sorter (Becton 
Dickinson).
RNA isolation, cDNA synthesis, and polymerase chain reaction 
amplification. RNA was isolated from the sorted cell pellet using the 
RNAzol method (Cinna/Biotecx Laboratories, Houston, TX), dis- 
solved in 25 jul of distilled water, and stored at ~80°C. Five micro- 
' grams of RNA were reversed transcribed into first-strand cDNA 
using the Riboclone cDNA synthesis system (Promega, Madison, 
WI). cDNA was quantified with control primers and diluted to an 
amount where 1 pi of cDNA resulted in polymerase chain reaction 
(PCR) products in a log phase of expansion for each primer used. 
cDNA was stored at -20°C. The TCRBV repertoire was analyzed 
using 25 TCRBV-specific primers identifying 24 different TCRBV 
families, as described previously (20, 31). For each PCR, 1 jul of cDNA 
was used and added to a mixture of 20 pmol of 3' antisense TCRBC 
primer, 0.5 mM of dNTP, 10 mM Tris HCl (pH 8.4), 50 mM KCl, 4 
Sí mM MgCl2, 0.06 mg/ml bovine serum albumin, 2.5 U of AmpliTaq 
DNA polymerase (Perkin Elmer/Roche Molecular Systems Inc.,
Branchburg, NJ), and 20 pmol of each TCRBV-specifíc 5 ' senae 
primer in total volume of 100 /xl. Twenty-five to 35 P G R  cycle«, 
depending on the amount of cDNA, were performed in  a  therm ocycler 
(Biomed thermocycler 60, Biomed Instruments, F u lle r to n , CA). The 
PCR cycles consisted of a 95°C dénaturation step , a  5 5 ° O primer 
annealing step, and a 72°C extension step for 1 m in  e a c h . As an 
internal control, a 5' sense primer for the constant re g io n  o f  th û  T cell 
receptor was used. As a negative control, a PCR w ith o u t  a  tem plate 
was performed to exclude contamination. Five m ic ro l i te r s  of the 
PCR-amplified products were size fractionated on a  1% ag a ro se  gel 
and subsequently transferred to Hybond N+ nylon m e m b ra n e  (Am- 
ersham, Arlington Heights, IL). Hybridization w as p e rfo rm e d  using 
a [32P]-radiolabeled TCRBC-specific probe. S em iquanti t a t i  ve analy­
sis of each individual TCRBV PCR product was p e r fo rm e d  using 
phosphorus imaging (PhosphorImager 445SI, M o lecu la r Dynamics, 
Sunnyvale, CA). All TCRBV repertoire analyses w e re  perfo rm ed  in 
duplicate with correlation coefficients (R2) >0,95 b e tw e e n  two con­
secutive experiments.
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Evaluation of data. For the LDAs, the mean counts per second 
(europium, CTLp assay) or photometer values (pro pi drum iodide, 
mV, HTLp assay) and the standard deviation of the wells with 
stimulator and target cells only were calculated. A well was scored as 
positive if the counts in that well exceeded the mean H- 3SD of the 
wells with stimulator cells and corresponding target cells only. Pre­
cursor frequencies (expressed as the number of precursor cells per 
106 cultured cells) were calculated using the Strijbosch computer 
program (32), Precursor frequencies were taken into account only if 
the goodness of fit was ^15 (jackknife method) to assure single-hit 
kinetics (32), The statistical significance of the differences between 
certain time points after BT was analyzed using the Wilcoxon signed 
rank test. Comparisons of frequencies specific for the blood donor 
versus third-party cells were done using a two-sided Mann-Whitney 
analysis. Overall changes in the TCRBV were determined by corre­
lation coefficients (R2), with R2= l being a perfect correlation and 
R2=0 indicating no correlation between the TCRBV repertoires.
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RESULTS
CTLp frequencies. CTLp frequencies were determined be­
fore and at two time points after BT. Patients were divided 
into three groups: (1) patients who received an HLA class 
II-mismatched (nonshared) transfusion (n=3); (2) patients 
who received a transfusion with one HLA-DR antigen in 
common with the blood donor (one HLA-DR shared) and 
mismatched for HLA class I antigens (n=9); and (3) patients 
who received a transfusion with at least one HLA-B and one 
HLA-DR antigen in common with the blood donor (HLA- 
B-}-DR shared, n=8). Matching of patient and blood donor for 
HLA class I was based on serologically defined antigens, and 
for class II on HLA-DR broad antigens. CTLp frequencies 
against blood donor and third-party cells for the different 
patient groups are shown in Figures 1, 2, and 3. In group 1, 
an increase in CTLp frequencies against the blood donor was 
seen 2 weeks after BT (Fig. 1A). In two of three patients, the 
CTLp frequency subsequently decreased after an interval of 
more than 10 weeks after transfusion. In one patient (Dur), 
the frequency remained high (215/106 at 2 weeks, 235/106 at
10 weeks). Against third-party cells, no dramatic changes 
were seen in this group (Fig. IB). In group 2 (one-HLA-DR- 
shared BT), a significant increase in CTLp frequencies was 
observed against blood donor cells 2 weeks after BT 
(P=0.0039). These frequencies decreased to pretransfusion 
levels long after BT (Fig. 2A). Only in patient Ar did the 
frequency decrease to a level lower than the one observed 
before transfusion. This decrease was specific for blood donor 
cells, since the frequency against third-party cells did not 
decrease in this patient. Against third-party cells, no dra­
matic changes were seen in this group (Fig. 2B). In group 3 
(at least one-HLA-B+DR-shared BT), a significant increase 
in CTLp frequencies against blood donor cells was also ob­
served 2 weeks after BT (P=0.0156). Long after BT, the 
frequencies almost decreased to pretransfusion levels (Fig. 
3A). Against third-party cells, no dramatic changes were 
seen in this group (Fig. 3B), In conclusion, in the total group 
of patients, the CTLp frequencies never reached levels below 
the pretransfusion values (with the exception of patient Ar in 
group 2), irrespective of HLA disparity. However, the range 
of the >10-week samples was highly variable, which might 
explain why we could not detect the donor-specific CTLp 
nonresponsiveness observed by others after a HLA-B+ DR- 
matched BT (17). To test whether CTLp nonresponsiveness is 
a time-dependent phenomenon, the CTLp frequencies of all
B CTLpf anti 3d party
class II mismatched BT
Ma
Dur
Kam
F ig u re  1. CTLp frequencies (CTLpf) of patients (n=3) who received 
an HLA-mismatched BT measured before, 2 weeks after, and long 
after BT against blood transfusion donor (BTD) cells (A) or against 
third-party cells (B).
patients against the BT donor tested more than 10 weeks 
after BT were grouped according to the sampling time after 
BT (Fig. 4). No significant down-regulation of the donor- 
specific CTLp could be observed in one of these different time 
periods. Furthermore, no differences were observed between 
the CTLp frequencies measured in these separate time in­
tervals.
Inhibition with anti-CD8 antibodies. To study the effect of 
CD8 molecule blockade on CTLp frequencies, each respond­
er-stimulator combination was incubated with a noncytotoxic 
anti-CD8 monoclonal antibody 1 hr before target cells were 
added. In the total group of patients, the patterns of (anti- 
CD8 resistant) CTLp frequencies were similar, as described 
above (Fig. 5). A significant increase in frequencies of anti- 
CD8-resistant CTLp was seen 2 weeks after BT CP<0.0001). 
No differences were observed among the three groups of 
patients. When percentage of inhibition of CTLp by anti-CD8 
was calculated long after BT, lysis of blood donor-derived 
target cells could be less inhibited with anti-CD8 than lysis of 
third-party target cells (mean inhibition: 43% vs. 70%, 
P=0.0297).
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Figure 2. CTLp frequencies (CTLpf) of patients (n=9) who received 
an HLA-DR-shared BT measured before, 2 weeks after, and long 
after BT against blood transfusion donor (BTD) cells (A) or against 
third-party cells (B). ;|P=0.0039.
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F ig u re  3. CTLp frequencies (CTLpf) of patients (n=8) who received 
a BT that shared at least one HLA-B and one HLA-DR antigen 
measured before, 2 weeks after, and long after BT against blood 
transfusion donor (BTD) cells (A) or against third-party cells (B).
*P=0.0156.
HTLp frequencies. In four patients from group 2, who had 
received an HLA-DR-antigen-shared BT} the HTLp fre­
quency was investigated before, 2 weeks after, and >10 
weeks after BT (Fig. 6, A and B). In three of four patients, BT 
resulted in an increase of HTLp frequency against the blood 
donor 2 weeks after BT, which confirms earlier data obtained 
in 10 other patients (33). In contrast, such an increase was 
not observed against third-party cells. No correlation be­
tween changes in CTLp and HTLp frequencies was observed 
in these patients.
Analysis of TCRBV gene usage. Analysis of the TCRBV 
repertoire of CD4+ and CD8+ T cells revealed that in 5 of 10 
patients the overall repertoire remained stable after BT. 
However, in the remaining five patients a modulation of the 
TCRBV gene usage was observed in either the CD4 or CD8 
population (R2<0.75), whereas the other subset remained 
relatively unaffected (Table 2). Changes in the repertoire of 
the CD4 or CD8 subset are displayed in Figure 6. In these 
subsets, BT resulted in expansions or contractions of one or 
more distinct TCRBV gene families. These changes seemed 
patient specific, and general patterns with respect to these
CTLpf anti BTD
(g ro u p e d  b y  sam p lin g  tim e )
time in months
F ig u re  4. CTLp frequencies (CTLpf) of all patients against blood 
transfusion donor (BTD) cells grouped according to sampling time. In 
every column, the mean frequency is depicted with a horizontal line.
1150 TRANSPLANTATION Vol. 63, No. 8
A
10000-
'O© tOOOl
o- 100 -=
10-
1J
CTLpf anti BTD + anti-CD8
total group of patient
A
before BT 2w after >10 weeks
--------À '
Ka
Ma
Ve
Jo
Ra
Ko
Kp
Wa
Be
Du
Ad
Dur
Kam
Vv
KI
Op
Ba 
Bu
SI 
Ar
Thfanti BTD
1 DR shared BT
Ba
Bu
SI
Ar
B
1000 -=
MD
rH io<h
s
u 10“
1
CTLpf anti 3d party +
anti-CD8
total group of patients
before BT
--------------- !----------------
2w after
---------------------i--------------------
> 10 weeks
-tsr
Ka
Ma
Ve
Jo
Rii
Ko
Kp
Wa
Be
D u
Ad
D ur
Kam
Vv
KI
Öp
Ba
Bu
SI
A t
F ig u re  5. CD8 antibody-resistant CTLp frequencies (CTLpf) of all 
patients (n~20) against blood transfusion donor (BTD) cells (A) or 
against third-party cells (B) *P<0.0001.
B
Thf anti 3d party
1 DR shared BT
Ba
Bu
SI
Ar
Figure 6. HTLp frequencies (Thf) of patients (n=4) who received an 
HLA-DR-shared BT measured before, 2 weeks after, and long after 
BT against blood transfusion donor (BTD) cells (A) or against third- 
party cells (B).
alterations were not observed. In some patients, the effect 
was limited to a few families (Fig. 7, A and D), whereas in 
other cases (Fig. 7, B, C, and E) the BT had a broader effect 
on the TCRBV repertoire. This is exemplified by patient Ve, 
who showed an increase in TCRBV22 from 5% before BT to 
more than 45% in the CD8 subset after receiving a one-DR- 
matched BT (Fig. 6A). When TCRBV22 was not included in 
the analysis of changes in the overall TCRBV repertoire, the 
R2 increased from 0.035 to 0.831, which suggests that these 
changes were mainly the result of an (oligo)clonal expansion 
of this gene family. This effect was still present, but less 
pronounced, at 41 months after BT. At the same time, a 
contraction of TCRBV2 occurred in this subset. Almost sim­
ilar results were observed in patient Op, in whom 2 weeks 
after receiving a B-t-DR shared transfusion more than 90% of 
the TCRBV repertoire of CD4+ PBMC consisted of TCRBV8 
(Fig. 7D). After 39 months, the usage frequency of this T cell 
receptor gene family decreased below pretransfusion values. 
Fewer restricted changes of the TCRBV repertoire were ob­
served in the other three patients, in whom BT resulted in an 
increase in the usage of certain TCRBV families, or a de­
crease in the usage of other TCRBV families (Figs. 7, B, C, 
and E). The contraction of several TCRBV families was not 
just the result of an expansion of other TCRBV, since the 
relative decrease of other TCRBV families was not distrib­
uted equally among the nonexpanding TCRBV families. Fur­
thermore, no correlation was observed between the degree of 
HLA sharing of the BT and the effect on TCRBV gene usage. 
In general, the impact of BT on the composition of the 
TCRBV repertoire of the CD4 and CD8 subset of T cells was 
independent of HLA sharing and exhibited an individual- 
specific character.
DISCUSSION
This study was performed to analyze possible mechanisms 
involved in the beneficial effect of BT on transplant survival. 
Because T cells are likely to play an important role in almost 
all immunoregiilatory mechanisms proposed and are respon­
sible for graft rejection, we investigated the T cell compart­
ment in patients who received a pretransplant BT. The re­
sults of our study show that, in the total group of patients, 
CTLp frequencies against the blood donor initially increase
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T a b le  2. Correlation coefficient (R2) between the TCRBV repertoire before and different time points after BT in CD4+ and CD8+ T
cell subsets
Patient“ HLA sharing Time after BT CD4 CD 8
1 Ma Mismatched 2 wk 0,882 0.897
6 mo 0.885 0.735
5 Bu 1DR 4 mo 0.902 0.899
6 SI 1DR 3 mo 0.935 0.953
8 Ka 1DR 2 wk 0.920 0.941
46 mo 0.905 0.617
9 Ve 1DR 2 wk 0.903 0.053
41 mo 0.910 0.035
13 Ra 1A IB IDE 2 wk 0-857 0.829
13 mo 0.886 NT6
14 Ko IB 1DR 2 wk 0.927 0.949
58 mo 0.919 0.877
18 Du 1A IB 1DR 2 wk NT 0.672
20 Op 1A IB 1DR 2 wk 0.014 0.765
39 mo 0.750 0.926
21 Vo 2A IB 2DR 2 wk 0.841 0.924
35 mo 0.839 0.804
“ Patient number corresponds to those used in Table 1. 
b NT, not tested.
a fte r  BT (,34) and eventually almost always reach (except for 
one patient in group 2) pretransfusion levels again long after 
BT (median, 19 months). The patterns of HTLp frequencies 
w ere comparable to those observed in CTLp frequencies. Two 
weeks after BT, increased levels of HTLp frequencies were 
found in three of four patients, confirming earlier data ob­
tained from another group of patients (33). An increased 
number of anti-CD8-resistant CTLp against the blood donor 
w ere found long after BT, indicating that BT leads to high- 
avidity CTLs directed against antigens of the blood donor.
In  contrast to previous studies (17), we were not able to 
show any T cell nonresponsiveness against the donor, neither 
a fte r HLA-B+DR-shared BT nor after HLA-DR-shared BT, 
O ur results are in concordance with those of van Prooijen et 
al. (35), who reported that in 14 patients a single transfusion 
of HLA haplotype-matched, buffy coat-depleted blood gener­
ally  did not induce donor-specific down-regulation. After 
transfusion of HLA haplotype-matched whole blood, no do­
nor-specific down-regulation was seen at all (H.C. van Prooi­
jen , Department of Immun oh aem atol ogy, University Hospi­
ta l  Utrecht, The Netherlands, personal communication, 
1996). Different composition and storage conditions of blood 
products may account for the discrepancy between the re­
sults. Fresh blood containing viable leukocytes is necessary 
for the clinical effect (36), although others claim that stored 
blood is essential for the immunosuppressive effect in vivo 
(37) or in vitro (38). Characterization of blood products before 
administration is essential to monitor the immunological 
effects of BT in transplantation candidates.
In 5 of 10 patients, an expansion or contraction of one or 
more TCRBV families was observed after BT. These changes 
were limited in four cases to the CD8 T cell compartment and 
in  one case to the CD4 T cell compartment. In the other five 
patients, the TCRBV repertoire remained stable after BT. In 
most cases, the alterations concerned a limited number of 
TCRBV gene families and displayed an individual-specific 
pattern. No correlation was seen between the degree of HLA 
sharing and the CTLp or HTLp frequencies or in changes 
induced on TCRBV repertoire.
Our data do not confirm those of Munson et al. (19), who 
observed deletions in TCRBV families in patients who re­
ceived an HLA h apio type-shared BT, whereas a mismatched 
transfusion did not induce such deletions. Also, others have 
studied the effect of allorecognition on the T cell receptor 
gene (39). Mixed lymphocyte cultures revealed a restricted 
but heterogeneous TCRBV gene usage of alloreactive T cells 
(40-43). Carlquist et al. (44) demonstrated quantitative 
change of the TCRBV repertoire in PBMC of cardiac recipi­
ents just before rejection crisis. In healthy individuals who 
had not received transfusions, the TCRBV repertoire re­
mained stable over a period of 21 months (45). However, in 
vivo expansions of TCRBV families can be observed in 
healthy young individuals and might be the result of expo­
sure to environmental antigens (46, 47), Since the observed 
changes of one or more TCRBV families appeared within 2 
weeks after BT, they were most likely induced by the trans­
fusion and probably not a result of exposure to environmental 
antigens. In one patient (patient Op), changes in the TCRBV 
repertoire mimicked a response seen after exposure to supe­
rantigens (48). The expansion of TCRBV8 in CD4+ cells to 
more than 85% of the total repertoire observed 2 weeks after 
BT and a subsequent decrease below pretransfusion values 
are in line with this reasoning. This expansion could also 
represent proliferation of CD4* cells that have a down-reg­
ulating effect on donor-reactive cells in a subsequent trans­
planted organ (10,49). The question of whether the expanded 
TCRBV families specifically concern alloreactive T cells di­
rected against donor antigen(s) is a subject of future studies.
The present study strongly suggests that BT results in 
activation of the recipient T cell compartment against donor 
antigens rather than in induction of T cell tolerance. I t is 
unlikely that this activation of the T cell repertoire was due 
to natural variations in time, since it was shown th a t pre­
cursor frequencies to alloantigens do not alter significantly 
within normal individuals over several months (50). Our 
findings support the view of Terasaki (7) that BTs always 
immunize the recipient and do not induce tolerance. The 
transplant could act as a second stimulus, and in the pres-
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enee of immunosuppressive therapy, reactivated T cell clones 
are deleted, or at least reduced to ineffective numbers. This 
could explain that the activation of CTLp and HTLp directed 
against donor antigens, as found in our patients, is associ­
ated with better graft survival. However, this does not ex­
plain the observation tha t HLA-DR or haplotype sharing of 
the patient with the blood donor leads to better transplanta­
tion results than mismatched BT.
In conclusion, our in vitro studies demonstrate that BT, 
irrespective of the degree of HLA matching, leads to activa­
tion of the T cell compartment. The determination of donor- 
specific CTLp-HTLp frequencies and TCRBV repertoire after 
BT does not give a direct clue to the mechanism involved in 
the beneficial effect of (donor-specific) BT on graft survival.
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